Forbes: Psychedelic Pioneer Rick Doblin On FDA Trials Of MDMA: Most Important Reality Check Of MAPS’ 34-Year History

Summary: Forbes reports on the results from MAPS’ interim analysis for the first of two Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD, a monumental milestone in psychedelic research. “The great results from the interim analysis has changed everything in that we are now actively preparing for FDA approval and commercialization based not on hopes and dreams but on actual data from Phase 3,” explains MAPS Founder Rick Doblin, Ph.D.

Originally appearing here.